Pages
Products
Synapsin-GFP AAV (Serotype 9)

Synapsin-GFP AAV (Serotype 9)

Cat.No. :  AAV00106Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00106Z
Description Synapsin-GFP AAV (Serotype 9) is the serotype 9 AAV which express eGFP under the Synapsin promoter which restricts transgene expression only in neurons.
Reporter GFP
Serotype AAV Serotype 9
Target Gene Synapsin-GFP
Product Type Adeno-associated virus
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

AAV9 is a human AAV serotype that has greatly improved transduction efficiency in cardiac and skeletal muscle, liver and pancreatic tissue, and the eye compared to other serotypes. Given its tissue tropism, AAV9 is being developed for a variety of therapeutic gene delivery applications, such as cardiac and ocular diseases and coagulation disorders such as hemophilia A and B. AAV9 can also cross the blood-brain barrier and, among all AAVs, targets the central nervous system with high efficiency. Recently, a single intravenous injection of an AAV9 vector expressing α-N-acetylglucosaminidase (NAGLU) in mice with mucopolysaccharidosis IIIB (MPS IIIB; a lysosomal storage disorder) corrected lysosomal storage pathology in the central and peripheral nervous systems and corrected astrocytosis and neurodegeneration. Given these properties, AAV9 is currently being developed for the treatment of neurodegenerative diseases such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's disease, and MPS IIIB. Furthermore, although AAV antibodies have been shown to be detrimental to AAV gene delivery, the prevalence of AAV9 antibodies in humans is lower than that of other serotypes (e.g., AAV1 and AAV2), making this serotype a more attractive candidate as a gene delivery vector.

Reduced insulin-like growth factor 1 (IGF-1) is associated with cognitive impairment and increased risk of neurodegenerative diseases in advanced age. The researchers hypothesized that IGF-1 continues to promote the structure and function of hippocampal neurons after development and therefore, loss of IGF-1 signaling in adult neurons would result in impaired spatial learning and memory. To test this, the IGF-1 receptor (IGF-1R) was genetically targeted in hippocampal neurons of adult male and female mice. Male mice deficient in neuronal IGF-1R exhibited spatial learning impairments as evidenced by increased path length and errors in the radial arm water maze. There were no differences in learning and memory in female mice. Golgi-Cox staining revealed a reduction in the number of dendrites in neurons in the CA1 region of the hippocampus of male mice. Decreased MAPK and increased ROCK activity were also observed in these tissues. In vitro studies showed that the impaired neurite outgrowth due to inhibition of IGF-1R signaling could be rescued by pharmacological inhibitors of ROCK. However, ROCK inhibition did not fully rescue learning impairments or synaptic nuclei number in mice deficient in neuronal IGF-1R. Altogether, these findings highlight that IGF-1 continues to support spatial learning and memory as well as neuronal architecture in adulthood.

Hippocampal neuron-specific IGF-1R deletion (*IGFR-KO) was induced in male and female igfrf/f mice at 3-4 months of age by stereotaxic injection of Cre recombinase encoding a viral vector (AAV9-Syn-Cre or control AAV9-Syn-GFP) (Figure 1A). The mRNA expression of IGFR, IGF-1, and other growth-promoting signals was quantified in the dorsal hippocampus to verify the specific reduction of the floxed region of IGF-1R exon 3. These neuron-specific *IGFR-KO male and female mice had a 39.6% reduction in IGF-1R compared with GFP-transduced controls (*IGFR-WT) (Figure 1B). No significant differences in growth hormone receptor (GHR), insulin receptor (InsR), or IGF-1 expression were observed in the hippocampi of *IGFR-KO mice (Figure 1B). Both *IGFR-WT and *IGFR-KO mice learned how to find the escape platform during the three-day training phase, as evidenced by a reduction in the total path length to the escape platform (Figure 1C) and a reduction in the total number of errors in finding the platform (Figure 1E). However, *IGFR-KOs traveled significantly more and made more errors than controls throughout the learning phase (Figure 1C and E). When memory extinction and relearning were assessed during the reversal phase of the maze, male *IGFR-KO mice again traveled significantly more and made more errors than controls (Figure 1D and F).

Adult IGF-1R Signaling in Neurons Regulates Spatial Learning and Memory in Male Mice.Figure 1. Adult IGF-1R Signaling in Neurons Regulates Spatial Learning and Memory in Male Mice. (Hayes C A, et al., 2021)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Efficient Gene Delivery

The Synapsin-GFP AAV (Serotype 9) has proven to be an incredibly reliable tool in our research. Its high efficiency in transducing neurons has made our gene delivery process seamless and effective, ensuring consistent results in our experiments.

French

09/26/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction